Strides gets USFDA nod for constipation drug
New Delhi : Strides Shasun has received an approval from the US health regulator for Polyethylene Elycol 3350 used for treating constipation.
In a BSE filing, Strides Shasun today said: "It has received approval from the US Food and Drug Administration (USFDA) for Polyethylene Glycol 3350, powder for solution 17 grams/capful and 17 grams/packet (OTC)."
The company said it will manufacture the product at its Bengaluru plant and launch it in the fourth quarter of this fiscal.
Quoting IMS sales data, Strides Shasun said the US market for Polyethylene Glycol 3350, powder for solution is around $260 million.
Strides Shasun shares were trading 0.88 per cent higher at Rs. 973.50 apiece on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd